ClinicalTrials.gg
RecruitingNCT07229781Updated Oct 5, 2026

Mediterranean Diet and Blood Sugar Study

An interventional study of Mediterranean-style diet with potatoes and Traditional-style Mediterranean diet in Prediabetes, sponsored by Penn State University. Recruiting at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Penn State University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 5, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 390 studies in Prediabetic State with a site in United States — 83 open to participants now, 107 under way, 2 of them phase 3. Prediabetic State · United States.

Planned enrollment
137th of 362
74 · median 54
Started
2026
with 38 others
No phase
288 of 390
58 open now
Primary completion
2028-04
later than 76 of 106 live
Registered
355th of 390
by date

Among the 390 studies in Prediabetic State with a site in United States, this one is the 137th largest by planned enrollment of the 362 interventional ones that give a count, is one of 39 that started in 2026, is one of 288 with no phase, reaches primary completion later than 76 of the 106 other live ones, and was the 355th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

83 of the 390 studies in Prediabetic State with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Prediabetic State with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to determine if a healthy Mediterranean diet containing one medium potato/day has equivalent or non-different effects on risk factors for type 2 diabetes and heart disease compared to a healthy Mediterranean diet without potatoes in adults with prediabetes. Participants will be randomly assigned to one of the test diets and be asked to consume this diet for 12 weeks (84 days). Testing will be conducted at the beginning and end of the study.

Read the detailed description

This is a 12-week, 2-arm parallel, randomized controlled feeding trial. Participants will be randomized to either a Mediterranean-style diet that includes 1 medium potato/day/2000 kcal replacing some grains , or a traditional-style Mediterranean dietary pattern without potatoes. All food will be provided for the 12-week study duration.

03

Conditions studied

  • Prediabetes

Keywords

  • prediabetes
  • diet
  • nutrition
  • Mediterranean diet
  • cardiovascular disease
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 25-65 years
  • Prediabetes assessed by an of 5.7-6.4% or fasting glucose 100-125 mg/dL at screening
  • 25-40 kg/m2 at screening

Exclusion criteria

Exclusion Criteria:

  • ≥6.5% at screening
  • LDL-C (calculated with the Martin-Hopkins equation) ≥190 mg/dL at screening
  • \<13.2 g/dL at screening
  • Fasting triglycerides >350 mg/dL at screening

    -≥10% change in body weight within the 6 months prior to enrollment

  • Blood pressure >140/90 mmHg at screening
  • Type 1 or type 2 diabetes
  • Prescription of anti-hypertensive, lipid-lowering, or glucose-lowering drugs
  • Intake of supplements that affect the outcomes of interest (i.e., lipid, blood pressure, or glucose lowering; vitamin C or multi-vitamins containing vitamin C) and are unwilling to cease during the study period.
  • History of liver, kidney, or disease
  • Prior cardiovascular event (e.g., stroke, heart attack)
  • Current pregnancy or intention of pregnancy within the next 6 months
  • Lactation within the prior 6 months
  • Allergy/intolerance/sensitivity/dislike of any foods in the study menus
  • Antibiotic use within the prior 1 month
  • Oral use within the prior 1 month
  • Use of tobacco or nicotine-containing products within the past 6 months
  • History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence)
  • Participation in another clinical trial within 60 days of baseline
  • Currently following a restricted or weight-loss diet
  • Prior bariatric surgery
  • Intake of >14 alcoholic drinks/week and/or not willing to avoid alcohol consumption for 48 hours prior to test visits
  • Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits
  • Does not speak and/or understand English
  • Unwilling to refrain from donating blood during the study
  • Weight \<110 lb
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Mediterranean-style diet with potato (MED-P)

    Mediterranean-style diet that includes 1 medium potato/day/2000 kcal replacing some grains

    Other: Mediterranean-style diet with potatoes

  • Active comparator
    Traditional-style Mediterranean dietary pattern (MED)

    A traditional-style Mediterranean diet that does not contain potatoes (potatoes are not a defining feature of this diet) and is higher in grains.

    Other: Traditional-style Mediterranean diet

Interventions

  • OtherMediterranean-style diet with potatoes

    The diet will contain 1 medium potato/day/2000 kcal

  • OtherTraditional-style Mediterranean diet

    Traditional-style Mediterranean diet higher in grains

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    HbA1c will be assessed at baseline and 12-weeks and expressed as percentage . The change in HbA1c will be calculated by subtracting the baseline value from the 12 week value and expressed as percentage point change.

    Time frame: 12-weeks

Secondary outcomes

  1. Change in fasting glucose

    Change in fasting plasma glucose expressed as mg/dL. Change in glucose will be calculated as the mean of the 12 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  2. Change in mean glucose

    Change in mean glucose assessed by a continuous glucose monitor (CGM) expressed as mg/dL. Change in mean glucose will be calculated as mean glucose assessed from 7 days of CGM wear at 12 weeks minus mean glucose assessed from 7 days of CGM wear at baseline.

    Time frame: 12-weeks

  3. Change in mean time in range

    Change in mean time in range (glucose 70-140 mg/dL) assessed by a continuous glucose monitor (CGM) expressed as minutes per day. Change in mean time in range will be calculated as mean time in range assessed from 7 days of CGM wear at 12 weeks minus mean time in range assessed from 7 days of CGM wear at baseline.

    Time frame: 12-weeks

  4. Change in glycemic variability

    Change in mean glycemic variability assessed by a continuous glucose monitor (CGM) expressed as the coefficient of variability. Change in mean glycemic variability will be calculated as mean glycemic variability assessed from 7 days of CGM wear at 12 weeks minus mean glycemic variability assessed from 7 days of CGM wear at baseline.

    Time frame: 12-weeks

  5. Change in fasting insulin

    Change in fasting serum insulin expressed as micro IU/mL. Change in insulin will be calculated as the mean of the 12 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  6. Change in homeostatic model of insulin resistance (HOMA-IR)

    Homeostatic model of insulin resistance (HOMA-IR) will be calculated from insulin and glucose measured from a fasting blood sample. Calculated as (insulin × glucose) / 22.5. Change in HOMA-IR will be calculated as the mean of the 12 week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  7. Change in LDL-Cholesterol

    Assessed from fasting blood draw expressed in mg/dL. Change in LDL-cholesterol will be calculated as the mean of the 12-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  8. Change in apolipoprotein B

    Assessed from fasting blood draw expressed in mg/dL. Change in apolipoprotein B will be calculated by subtracting the baseline value from the 12 week value.

    Time frame: 12-weeks

  9. Change in non-HDL cholesterol

    Assessed from fasting blood draw expressed in mg/dL. Change in non-HDL cholesterol will be calculated as the mean of the 12-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  10. Change in Total Cholesterol

    Assessed from fasting blood draw expressed in mg/dL. Change in total cholesterol will be calculated as the mean of the 12-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  11. Change in HDL-Cholesterol

    Assessed from fasting blood draw expressed in mg/dL. Change in HDL-cholesterol will be calculated as the mean of the 12-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  12. Change in Triglycerides

    Assessed from fasting blood draw expressed in mg/dL. Change in triglycerides will be calculated as the mean of the 12-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  13. Change in C-reactive protein

    Assessed from fasting blood draw expressed in mg/L. Change in C-reactive protein will be calculated as the mean of the 12-week measures (i.e., mean of day 1 and day 2 values) minus the mean of the baseline measures (i.e., mean of day 1 and day 2 values).

    Time frame: 12-weeks

  14. Change in Central Systolic and Diastolic Blood Pressure

    Central blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline \& 12 weeks. Change will be calculated by subtracting the baseline value from the end point value.

    Time frame: 12-weeks

  15. Change in Peripheral Systolic and Diastolic Blood Pressure

    Peripheral blood pressure measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline \& 12 weeks. Change will be calculated by subtracting the baseline value from the end point value.

    Time frame: 12-weeks

  16. Change in Carotid-Femoral Pulse Wave Velocity

    Measured assessed using a SphymoCor Xcel (Atcor Medical) at baseline \& 12 weeks. Change will be calculated by subtracting the baseline value from the end point value.

    Time frame: 12-weeks

  17. Change in particle size and number of LDL, HDL, triglyceride rich lipoproteins

    Measured via Nuclear Magnetic Resonance

    Time frame: 12-weeks

  18. Diet Satisfaction

    Participants will complete a survey that we have previously developed to assess diet satisfaction at 12 weeks.

    Time frame: 12-weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Time frame: The SAP and protocol will be posted on clinicaltrials.gov prior to enrollment commencing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Apr 2028, 20 months after the start.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 20 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Aug 26, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
1 site added — first site in United States
Show site
  • The Pennsylvania State University · University Park, United States
Oct 5, 2026
Start date
Aug 1, 2026→Aug 26, 2026 (actual)
Oct 5, 2026
Sponsor
Collaborators added: Alliance for Potato Research and Education; collaborators removed: Alliance for Potato Research & Education
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • The Pennsylvania State University · University Park, United States
    Start date Aug 1, 2026→Aug 26, 2026 (now actual)
    Sponsor Collaborators added: Alliance for Potato Research and Education; collaborators removed: Alliance for Potato Research & Education
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07229781
Collaborators
Alliance for Potato Research and Education
Responsible party
Kristina Petersen PhD, APD, FAHA (Associate Professor, Penn State University) — Principal investigator
First posted
Nov 17, 2025
Start date
Aug 26, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Kristina Petersen, PhD
Contact
kup63@psu.edu
814-865-7206
Stacey Meily
Contact
sas117@psu.edu
814-863-8622

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion